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Abstract
Background: The pathogenesis of diabetic cardiomyopathy (DCM) involves the enhanced activation of peroxisome
proliferator activating receptor (PPAR) transcription factors, including the most prominent isoform in the heart,
PPARα. In cancer cells and adipocytes, post-translational modification of PPARs have been identified, including
ligand-dependent degradation of PPARs by specific ubiquitin ligases. However, the regulation of PPARs in
cardiomyocytes and heart have not previously been identified. We recently identified that muscle ring finger-1
(MuRF1) and MuRF2 differentially inhibit PPAR activities by mono-ubiquitination, leading to the hypothesis that
MuRF3 may regulate PPAR activity in vivo to regulate DCM.
Methods: MuRF3−/− mice were challenged with 26 weeks 60 % high fat diet to induce insulin resistance and DCM.
Conscious echocardiography, blood glucose, tissue triglyceride, glycogen levels, immunoblot analysis of intracellular
signaling, heart and skeletal muscle morphometrics, and PPARα, PPARβ, and PPARγ1 activities were assayed.
Results: MuRF3−/− mice exhibited a premature systolic heart failure by 6 weeks high fat diet (vs. 12 weeks in
MuRF3+/+). MuRF3−/− mice weighed significantly less than sibling-matched wildtype mice after 26 weeks HFD. These
differences may be largely due to resistance to fat accumulation, as MRI analysis revealed MuRF3−/− mice had
significantly less fat mass, but not lean body mass. In vitro ubiquitination assays identified MuRF3 mono-ubiquitinated
PPARα and PPARγ1, but not PPARβ.
Conclusions: These findings suggest that MuRF3 helps stabilize cardiac PPARα and PPARγ1 in vivo to support
resistance to the development of DCM.
MuRF3 also plays an unexpected role in regulating fat storage despite being found only in striated muscle.
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Background
The MuRF3 (Trim54) ubiquitin ligase was the first
muscle-specific RING-finger (MuRF) protein identified
by its interaction with the serum response factor (SRF)
transcription factor [1]. The three MuRF family mem-
bers: MuRF1 (Trim63), MuRF2 (Trim55), and MuRF3
encode highly homologous proteins that both homo-
and hetero-dimerize via their coiled-coil regions [2].
During muscle atrophy, MuRF1 and MuRF2 translocate
to the nucleus in cardiomyocytes [3, 4] and act to
inhibit gene expression via their regulation of tran-
scription factors [5, 6]. MuRF1 and MuRF3 have been
localized to the Z-disk [1, 2]. Both MuRF2 and MuRF3
co-localize with stable glutamylated microtubules dur-
ing muscle assembly in vitro [1, 4] and in the early
stages of cardiomyocyte sarcomere assembly in vivo
[7, 8]. The association of MuRF proteins with microtu-
bules suggests their potential role in regulating micro-
tubule stability.
With expression limited to striated muscle, MuRF3 is a
required protein for skeletal myoblast differentiation and
support of the microtubule network [1]. Experimentally
reducing MuRF3 expression during myocyte development
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results in a severe disruption of sarcomeric Z and M-band
formation, likely due to these effects on tubulin dynamics
[7]. MuRF3 expression increases postnatally and is found
in both type I and type II muscle fibers [8]. The struc-
tural importance of MuRF3 has been demonstrated in
MuRF3−/− mice, where a predisposition to cardiac rup-
ture after MI has been reported [9]. Its role in the turn-
over of myosin heavy chain has been previously described.
MuRF3 ubiquitinates myosin heavy chain, targeting it for
degradation, indicating its role in myosin protein quality
control [10]. The closely related MuRF1 family member
similarly regulates myosin protein quality control; mice
lacking both MuRF3 and MuRF1 exhibit the development
of classic skeletal muscle myopathy, characterized by an
accumulation of myosin [10]. Both diabetes and treat-
ment with the chemotherapy doxorubicin increases car-
diac MuRF3 expression (http://www.ncbi.nlm.nih.gov/
geoprofiles/50107288) [11].
Initial studies in our laboratory identified that MuRF1
specifically regulates PPARα, but not PPARβ, or PPARγ
activity both in vitro and in vivo [12, 13]. In the present
study, we hypothesized that MuRF3−/− hearts would
similarly regulate PPAR isoforms given the overlapping
specificities of MuRF family proteins for specific sub-
strates (myosin) and overlapping MuRF1−/−, MuRF2−/−,
and MuRF3−/− altered cardiac metabolomics profiles re-
cently identified by our laboratory [14]. With preliminary
evidence that MuRF3−/− mice demonstrated increased
levels of PPAR activity, we challenged them with a high fat
diet model of diabetic cardiomyopathy. Since free fatty
acids from the diet are the primary ligands for PPARs and
one of the mechanisms driving diabetes induced cardio-
myopathy, we hypothesized that MuRF3−/− mice would
exhibit an enhanced cardiomyopathy and cardiac hyper-
trophy given MuRF3’s role in regulating PPARs and poten-
tially SRF in vivo.
Methods
Animals and high fat diet-induced diabetic
cardiomyopathy model
All experiments described used age-matched mice or lit-
termates, male and female. All experiments were approved
by the Institutional Animal Care and Use Committee
(IACUC) review boards at the University of North Carolina
and were performed in accordance with federal guidelines.
MuRF3−/− mice, recently described and characterized
[14], with strain-matched wildtype mice ~10 weeks of age
were fed a high fat diet (60 % fat, 20 % protein, and 20 %
carbohydrates) for 26 weeks as previously described [15].
Baseline body weight, blood glucose, serum insulin, serum
triglyceride, and total cholesterol levels along with cardiac
function were obtained prior to starting the diet. Mice
receiving a high fat diet had body weight, blood glucose,
and serum insulin levels measured every two weeks and
echocardiography was performed every three weeks. An
MRI was performed at baseline, 6, 12, and 22 weeks to de-
tect body composition changes. After 26 weeks, mice were
anesthetized with isoflurane, euthanized with cervical spine
dislocation, and heart, liver, gastrocnemius, soleus, and
tibialis anterior muscles were collected in cryovials, flash
frozen, and stored at -80C.
Mouse echocardiography
Conscious cardiac transthoracic echocardiography was
performed on mice at the indicated time points using a
VisualSonics Vevo 2100 ultrasound biomicroscopy system
(VisualSonics, Inc., Toronto, Ontario, Canada). Investiga-
tors were blinded to mouse genotype. Two-dimensional
M-mode echocardiography was performed in the paraster-
nal long-axis view at the level of the papillary muscle on
loosely restrained mice. Anterior and posterior wall thick-
ness was measured as distance from epicardial to endo-
cardial leading edges. Left ventricular internal diameters
were also measured. Left ventricular systolic function
was assessed by ejection fraction (LV EF% = [(LV Vol; d-
LV Vol; s/LV Vol; d) × 100] and fractional shortening
(%FS = [(LVEDD – LVESD)/LVEDD] × 100). Measure-
ments represent the average of three cardiac cycles from
each mouse.
Body composition measurement
Conscious low-resolution nuclear magnetic resonance
imaging was used to measure body composition of each
mouse at baseline, 6, 12, and 22 weeks using an EchoMRI
3-in-1 Body Composition Analyzer for Live Small Animals
(Mice)(EchoMRI, LLC, Houston, TX) [16]. Body fat and
lean body mass was then calculated as a proportion of
total body weight collected just prior to analysis as previ-
ously described [17].
Blood collection, serum separation, and methods for
glucose, insulin, triglyceride, and total cholesterol
measurements
After overnight fast, ~200 μl whole blood was collected by
submandibular vein lancet bleed (glucose) or brachial sinus
puncture (remaining assays). One μl whole blood was ana-
lyzed via glucometer (PrecisionXtra, Abbott Diabetes Care
Inc., Alameda, CA, USA) and test strip (Abbott Diabetes
Care Ltd., Witney, Oxfordshire, UK). Blood collected in
serum separator tubes for the remaining tests was incu-
bated on ice for 90 min, and centrifuged at 1600 × g
(20 min at 4 °C). Insulin levels were measured using the
Insulin Enzyme Immunoassay Kit (Cayman Chemical,
Cat.#589501, Ann Arbor, MI 48108) according to the
manufacturer’s instructions as previously described [18].
Serum triglyceride and cholesterol levels were measured
using an automated chemical analyzer (Vitro 350, Ortho-
Clinical Diagnostics Company, Rochester, NY).
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Fatty acid extraction and triglyceride assay
Fatty acid extraction and tissue triglyceride concen-
trations were determined on flash frozen heart tissue,
liver tissue, and skeletal tissue as previously described
[19]. Briefly, 25–50 mg of heart, liver and skeletal muscle
was homogenized 15–30 s with a bladed homogenizer
(Power Gen 125, Cat.#14-261, setting 6, Fisher Scientific,
Inc., Pittsburgh, PA) in 10X (v/w) ice cold lysis buffer
(20 mM Tris base, 1 % Triton-X100, 50 mM NaCl,
250 mM NaF, 5 mM Na4P2O7-10H2O, 1 tablet protease
inhibitor (Roche Inc., Cat.#11836153)) and incubated at
4 °C for 1 h. Two hundred μl of homogenate was trans-
ferred to chloroform resistant tubes, mixed with 0.4 ml
methanol and 0.8 ml chloroform, placed on the rocker
at 4 °C for at least 30 min. Potassium chloride (0.24 ml
0.88 % KCl) was added, samples vortexed, and centri-
fuged at 1000 × g for 15 min at 4 °C. The bottom layer
of CHCl3 was then transferred and this process was re-
peated with another 0.8 ml of chloroform and the com-
bined CHCl3 layers were then dried under N2. One
hundred μl of a tert-butanol:methanol:Triton X-100 so-
lution (3:1:1, v/v/v) was added to each tube and samples
were stored at −20 °C. Glycerol standard 2.5 mg/dl
(Sigma, Inc., Cat.#G1394), free glycerol reagent (Sigma
Aldrich, Inc., Cat.#F6428) and triglyceride reagent
(Sigma Aldrich, Inc., Cat.#T2449) were used to meas-
ure triglyceride concentrations. Five μl of samples were
added to a 96-well plate. Working reagent was added
to the samples (4 volumes of free glycerol reagent: 1
volume of triglyceride reagent). This was left to in-
cubate, rocking, at room temperature for 15 min. Then
absorbance was measured per sample at 540 nm using
the Clariostar High Performance Multimode Microplate
Reader (BMG LABTECH, San Francisco, CA) and normal-
ized to tissue weight.
Tissue glycogen assay (Acid Hydrolysis Method)
Tissue glycogen was measured from heart, liver and skel-
etal muscle using a colorimetric tissue glycogen assay kit
(Sigma, Inc., Cat.#G3293) as previously described [20].
Briefly, 15–25 mg of tissue was powdered in liquid nitro-
gen, collected in a pre-chilled 2 ml tube, 0.5 ml 1 N HCl
added, then homogenized with a bladed homogenizer
(Fisher Scientific, Power Gen 125, Cat.#14-261, setting 6,
Pittsburgh, PA) under a hood. The resulting homogenate
(100 μl) was quickly added to 100 μl 1 N NaOH and kept
on ice until heated in HCl at 95 °C for 90 min, mixing
every 30 min, cooled to RT and 0.4 ml 1 N NaOH was
added to neutralize the sample. After the sample was
centrifuged at 14,000 × g for 10 min at RT, the super-
natant was used for glucose analysis using a hexokinase-
dependent assay kit (Sigma, Inc., Cat.#G3293) according
to the manufacturer’s instructions. Briefly, 10 μl (liver) or
20 μl (heart and gastrocnemius) of supernatant was put
into a 96-well plate, mixed with 200 μl of reagent, incu-
bated at room temperature for 15 min, and the absorbance
was measured at 340 nm.
RNA isolation and quantitative PCR analysis of
PPAR-regulated gene expression
Total RNA was isolated using TRIzol reagent according
to the manufacturer’s protocols (Life Technologies, Inc.,
Cat.#15596-026). About 25 mg of cardiac ventricular tis-
sue was put into TRIzol reagent and homogenized on
ice (Fisher Scientific, Power Gen 125, setting 5). Total
mRNA expression was determined using a two-step re-
action. cDNA was made from total RNA using the
iScript™ Reverse Transcription Supermix for RT-qPCR
kit (Cat.#170-8841, BIO-RAD), with a total volume of
20 μl per reaction. The complete reaction mix was incu-
bated in an Eppendorf Cycler (Hamburg, Germany)
using the following protocol: priming 5 min at 25C, re-
verse transcription 30 min at 42C, RT inactivation 5 min
at 85C. PCR products were amplified on a Roche Light-
cycler 480IIsystem using cDNA, Taqman Probes (Applied
Biosciences™), and Lightcycler 480 Probe Master Mix 2X
(Cat.#04 707 494 001). The TaqMan probes used in this
study were Mm00430615_m1 (ACC1), Mm00443579_m1
(ACOX1), Mm00475794_m1 (ADRP), Mm00599660_
m1 (LCAD), Mm00431611_m1 (MCAD), Mm00440939_
m1 (PPARα), Mm01305434_m1 (PPARβ), Mm00443325_
m1 (PDK4), Mm00487200_m1 (CPT1b), Mm00441480_
m1 (Glut1, Slc2a1), Mm01245502_m1 (Glut4, Slc2a4),
Mm01309576_m1 (PFK), Mm00432403_m1 (CD36, FAT),
Mm01185221_m1 (MuRF1, Trim63), and Mm01292963_g1
(MuRF2, Trim55), Mm00491308_m1 (MuRF3, Trim54),
Hs99999901_s1(18S), Mm00440359_m1(α-MHC, Myh6),
Mm00600555_m1(β-MHC,Myh7), Mm01255747_g1(ANP),
Mm00435304_g1(BNP), Mm00808218_g1(SK α-actin) (Ap-
plied Biosystems, Inc., Foster City, CA). Assay of PPARγ1
was performed using the Roche Universal Probe technol-
ogy, including forward primer (gggctgaggagaagtcacac) and
reverse primer (gggctgaggagaagtcacac) in conjunction with
UPL probe #92 (Roche, Inc., Cat.#04692098001). Samples
were run in triplicate and relative mRNA expression was
determined using 18S as an internal endogenous control.
RNase-free water, 2X Master Mix, Taqman Probe or Roche
UPL primer and probe, cDNA were used for each reaction.
Western blot
Western analysis of ventricular tissue was performed on
lysates created from ~25 mg tissue. Tissue lysates in Lysis
Buffer (Cell Signaling, Cat.#9803S) with XM β-glycerol
phosphate (Sigma, Cat.#G6251), protease inhibitor (Roche,
Cat.#11 836 153 001), and phosphatase inhibitor cocktail
(Roche Cat.#04 906 837 001) were manually homogenized
on ice (Fisher Scientific, Power Gen 125, setting 5) for 15–
20 s. Alternatively, tissue was placed in 8 M Urea Lysis
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Buffer (8 M Urea Sigma, Cat. #U0631, 5 M NaH2PO4
Sigma, Cat. #S3139, 1 M Tris-Cl pH 8.0) at a ratio of 15 μl
lysis buffer/mg of tissue and was homogenized at 4C
(TissueLyser LT, Qiagen, Cat. #85600) for 2 min. Homoge-
nates were incubated on ice for 30 min, centrifuged at
16,000 × g (4C) for 15 min and the supernatant stored
at -80C. Protein concentration was determined using the
Bio-Rad DC Protein Assay Reagent Package (Bio-Rad La-
boratories, Inc., Hercules, CA, Cat.#500-0116). Proteins
(30–50 μg/lane) were resolved on NuPAGE Bis-Tris or
Tris-Acetate 10 well gels. Mouse anti-NFκB p65, rabbit
anti-phospho-NFκB p65 (Ser536), rabbit anti-phospho-
NFκB p65 (Ser468) were used to measure NFκB signaling
(Cell Signaling Technologies, Cat.#4767, each 1:500). IRS-
1 signaling was detected using rabbit anti-phospho-IRS-1
(Ser1101) and rabbit anti-IRS-1 (Cell Signaling Technolo-
gies, Inc. Cat.#2385 and #2383, each 1:500). cJun signaling
was detected by rabbit anti-p-cJun (Ser73), rabbit anti-p-
cJun (Thr91) or rabbit anti-cJun 60A8 (Cell Signaling
Technologies, Cat.#9164, #2303, #9165, each 1:500). Pri-
mary antibodies were diluted in 4 % BSA/TBS-T and incu-
bated at 4 °C overnight. HRP-labeled secondary antibodies
against mouse (Sigma #A9917, 1:10,000) and rabbit (Sigma
#A9169, 1:5,000) were used to detected the primary anti-
bodies diluted in 1X TBS-T and incubated 1 h at room
temperature. Mouse anti-β-actin (Sigma, Inc., Cat.#A2228,
1:4000) was used as a loading control throughout. Secondary
antibody HRP was detected using ECL Select (GE Health-
care, Cat.#RPN2235) and imaged using the MultiDoc-it
Imaging System (UVP, LLC Ultra-violet Products, Ltd.,
Upland, CA).
Total O-GlcNAc expression
Total O-GlcNAc expression was determined by SDS-
PAGE as previously described [21], using anti-O-GlcNAc
(RL-2, Santa Cruz Biotechnology, Santa Cruz CA) on
PVDF blocked with 1 % bovine serum albumin dissolved
in TBS-T solution for 20 min, followed by an overnight
incubation with O-GlcNAc antibody (1:1000) at 4 °C.
Secondary antibody (goat-anti-mouse IgG-HRP, Santa
Cruz Biotechnologies, Santa Cruz CA; 1:4000) incubated
for 1 h at RT, washed with TBS-T, then visualized with
enhanced chemiluminescence (ECL) on the ChemiDoc™
XRS+ system with Image Lab™ Software v2.0 (Bio-Rad
Laboratories, Hercules CA). Total O-GlcNAcylation (per
lane) was quantified by the adjusted percentage volume -
intensity units of pixels of band ×mm2 - after background
subtraction using Quantity One Software v4.6.9 (Bio-Rad
Laboratories, Hercules CA), and normalized to β-actin
(Abcam, Cambridge MA).
In vitro ubiquitination assay
Human recombinant GST-E1 (50 nM, Boston, Biochem,
Cambridge, MA, Cat.#E-306), human recombinant UbcH5c/
UBE2D3 (2.5 μM, Boston Biochem, Inc., Cambridge, MA,
Cat.#E2-627), human recombinant ubiquitin (250 μM,
Boston Biochem, Inc., Cat.#U-100H), human MuRF3
recombinant protein (1 mg, LifeSensors, Cat.#UB306,
Malvern, PA), human PPAR-α, −β, and -γ recombinant
protein (500 ng, Sigma-Aldrich, Inc., St. Louis, MO,
Cat.#SRP2043, Cat.#SRP2044, and Cat.#SRP2045, respect-
ively) were added to reaction buffer (50 mM HEPES,
pH 7.5) containing 5 mM MgATP solution (Boston
Biochem, Inc., Cat.#B-20) and 0.6 mM DTT, then incu-
bated at 37 °C for 1 h. The reaction was stopped by adding
SDS-PAGE sample buffer and heating, then resolved on a
4-12 % Bis-Tris gel with MOPS running buffer (Invitrogen
Corp.) and transferred to PVDF membranes for im-
munoblotting with goat polyclonal anti-MuRF3 antibody
(Cat.#sc-50252, Santa Cruz Biotechnology), rabbit poly-
clonal anti-PPARα antibody (Cat.#Ab24509, Abcam),
rabbit polyclonal anti-PPARβ antibody (Cat.#AB10094,
Millipore), or rabbit polyclonal anti-PPARγ antibody
(Cat.#2443, Cell Signaling Technology).
Histology and cross-sectional area analysis
Hearts were perfused with 4 % paraformaldehyde, fixed
for 24 h, moved to 70 % ethanol, then process and em-
bedded in paraffin to be cut in 5 mm sections. Slides
were stained with H&E and Masson’s Trichrome (MT)
using standard procedures. Imaging of H&E and MT-
stained sections was obtained using Aperio Scanscope
and Aperio Imagescope software (version 10.0.36.1805,
Aperio Technologies, Inc., Vista, CA). MT-stained im-
ages were taken using Aperio Imagescope (TIFF) and
analyzed using NIH ImageJ using Aperio exported image
ruler. Cardiomyocyte cross-sectional area was measured
using Image J software. A minimum of 25 random fields
of the left ventricle at × 200 magnification were imaged
from at least three different sections from three bio-
logical replicates per experimental group.
Cross-sectional area analysis and fibrosis (%)
determination
Sections of the MT-stained tissue were analyzed in four
cross-sectional defined areas for arrangement and collagen
content histologically and quantitatively by using Meta-
Morph analysis (Molecular Devices). Controls served to
set the threshold against which the MuRF3−/− mouse sec-
tions were measured. Immunostaining for vimentin was
performed as described previously [22–24]. Briefly, cardiac
sections were stained with antibodies against Vimentin
(1:100, Cat. #SC-6260, Santa Cruz, Dallas, TX) or an ir-
relevant isotype mouse IgG (as a negative control) at 4 °C
overnight. Section were then treated with Alexa Fluor
488-conjugated secondary antibodies and counterstained
with 4,6-diamidino-2-phenylindole (DAPI)(Vector Labora-
tories, Burlingame, CA). Total positive vimentin stain cells
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were identified and counted in each of the four cross-
sectional defined areas using Meta-Morph software
(Molecular Devices). Images were taken using EVOS
XL Core cell imaging system (Life technologies).
Non-targeted metabolomics determination by GC-MS
Instrumentation
Cardiac tissue was flash frozen with liquid nitrogen
cooled in a biopress, a fraction weighted (~25-30 mg
weight), finely ground and added to fresh 50 % acetyl-
nitrile, 50 % water, 0.3 % formic acid at a standard
concentration of 25 mg/475 mcl buffer then fully homo-
genized on ice for 10–25 s and placed on dry ice/stored
at −80 °C. Samples were “crash” deprotonized by metha-
nol precipitation and spiked with D27-deuterated myristic
acid (D27-C14:0) as an internal standard for retention-
time locking and dried. The trimethylsilyl (TMS)-D27-
C14:0 standard retention time was set at *16.727 min.
Reactive carbonyls were stabilized at 50 °C with methox-
yamine hydrochloride in dry pyridine. Metabolites were
made volatile with TMS groups using N-methyl-N-
(trimethylsilyl) trifluoroacetamide or MSTFA with catalytic
trimethylchlorosilane at 50 °C. GC/MS methods generally
follow those of Roessner et al. (2000) [25], Fiehn et al.
(2008) [26], and Kind et al. (2009) [27], and used a 6890 N
GC connected to a 5975 inert single quadrupole MS
(Agilent Technologies, Santa Clara, CA). The two wall-
coated, open-tubular (WCOT) GC columns connected
in series were both from J&W/Agilent (part 122–5512),
DB5-MS, 15 m in length, 0.25 mm in diameter, with an
0.25-lm luminal film. Positive ions generated with conven-
tional electron-ionization (EI) at 70 eV were scanned
broadly from 600 to 50 m/z in the detector throughout
the 45 min cycle time. Data were acquired and analyzed as
previously described [14, 28].
Statistical analysis
Sigma Plot 11.0 and Prism were used to plot and statisti-
cally analyze data. Depending upon the experimental de-
sign, several statistical tests were applied to the studies.
Student’s t-test or One Way ANOVA followed by Holm-
Sidak pairwise post-hoc analysis was performed, indi-
cated in the figure legends. Significance was determined
as a p < 0.05. Values are expressed as mean ± SE. Statis-
tical analysis on metabolomics data was performed as
previously described [14, 28]. Metaboanalyst (v2.0) run
on the statistical package R (v2.14.0) used metabolite
peaks areas (as representative of concentration) [29, 30].
These data were first analyzed by an unsupervised prin-
cipal component analysis (PCA), which identified the
presence of the MuRF3 −/− after 26 weeks high fat diet
as the principal source of variance. To sharpen the sep-
aration between our two groups, data were next ana-
lyzed using a partial least squares discriminant analysis
(PLS-DA) to further determine which metabolites were
responsible for separating these two groups. The specific
metabolites contributing most significantly to the dif-
ferences identified by PLS-DA between MuRF3−/− and
wildtype control group hearts were determined using
the variable importance in projection (VIP) analysis in
the metaboanalyst environment. The metabolites that
best differentiated the groups were then individually
tested using the Student’s t-test (Microsoft Excel 2011,
Seattle, WA). The VIP and t-test significant metabolites
were matched to metabolomics pathways using the Pathway
Analysis feature in Metaboanalyst 2.0. Heat maps of the
metabolite data (individual and grouped) were generated
using the GENE E software (http://www.broadinstitute.org/
cancer/software/GENE-E/index.html).
Results
Initial studies in our laboratory identified that MuRF1 reg-
ulated PPARα, but not PPARβ, or PPARγ using PPAR-
response element (PPRE)-DNA binding assays [12, 13].
This led us to characterize PPAR isoform activities in our
MuRF3−/− mouse model. We hypothesized that MuRF3
−/− hearts would similarly regulate PPARα given the over-
lapping specificities of MuRF family proteins. Cardiac nu-
clei were isolated from MuRF3−/− hearts and assayed for
PPRE-DNA binding activity by ELISA, followed by specific
recognition of PPARα, PPARβ, or PPARγ (Fig. 1a). To our
surprise, all three PPAR isoforms were significantly ele-
vated in MuRF3−/− hearts compared to sibling wildtype
controls, with +60 % increase in PPARα, 300 % increase in
PPARβ, and +20 % increase in PPARγ in unchallenged
mice on a chow diet (Fig. 1a).
Given the critical role of cardiac PPARα, PPARβ, and
PPARγ1 in diabetic cardiomyopathy [31], we next chal-
lenged MuRF3−/− mice to a high fat diet (60 % fat, 20 %
protein, and 20 % carbohydrates) for 26 weeks (Fig. 1b)
as previously described [15]. In the context of diabetic
cardiomyopathy, we found that wildtype hearts exhibited
a 50 % increase in MuRF3 expression 26 weeks post-high
fat diet (Fig. 1c), a point in which insulin resistance and
hypertrophy were identified (described below). MuRF3−/−
and wildtype hearts did not significantly differ in heart
weight after 26 weeks high fat diet (Fig. 1d), but
MuRF3−/− mice had significant reductions in body weight
compared to strain-matched MuRF3+/+ mice (Fig. 1e).
To further delineate the pathological cardiac hyper-
trophy in MuRF3−/− mice, RT-qPCR analysis of fetal gene
expression was performed. As commonly found in the lit-
erature, αMHC was increased predictably along with
βMHC after 26 weeks of high fat diet, but did not differ
between MuRF3−/− and wildtype controls (Fig. 2a). Sig-
nificant reduction in brain natriuretic peptide (BNP) was
identified as reported in diabetic models of cardiomyop-
athy (Fig. 2a) [32]. Mechanisms that have been implicated
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in driving diabetic cardiomyopathy include hyperinsuline-
mia, which acts to stimulate PI3Ka/Akt-1 pathways by
which it mediates glucose uptake [33]. Akt-1 also activates
mTOR, downstream p70, and S6kinase-1 to increase
protein synthesis [33]. Therefore, we next investigated
blood glucose and serum insulin levels in fasting mice
in MuRF3−/− and wildtype controls (Fig. 2b). As ex-
pected, 26 weeks of high fat diet resulted in increased
fasting glucose and insulin levels (wildtype mice only),
consistent with insulin resistance. MuRF3−/− mice,
however, showed significantly lower blood glucose at
26 weeks high fat diet. Both MuRF3−/− and wildtype
mice exhibited significant increases after 26 weeks high
fat diet. Interestingly, at that time point, the MuRF3−/−
mice demonstrated significantly reduced glucose levels
compared to wildtype mice. This indicates that they are
more insulin sensitive.
As previously reported, MuRF3−/− hearts at baseline
did not differ from sibling wildtype controls [9, 14]. Des-
pite the lack of histological findings (Fig. 2c, Additional
file 1: Figure S1), MuRF3−/− hearts experienced signifi-
cant decreases in cardiac function by 6 weeks high fat diet
(Fig. 2d, 2e). Increases in cardiac LV mass were observed
after high fat diet, but when normalized for body weight,
MuRF3−/− hearts were not significantly increased after
26 weeks HFD (Fig. 2e, middle panel). Both MuRF3−/−
and wildtype hearts exhibited a progressive LV dilation
consistent with heart failure, evidenced by increases in LV
end diastolic dimension (Fig. 2e, right panel). With the
dynamic of heart failure and increasing cardiac mass,
increases in anterior and posterior wall thicknesses es-
sentially did not increase over time (Table 1), consistent
with the pathogenesis of diabetic cardiomyopathy and
characteristic cardiac hypertrophy [32, 34, 35].
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Fig. 1 Role of MuRF3 in regulating PPAR isoform activity and its role in high fat diet cardiac hypertrophy in vivo. Isolation of cardiac nuclei from
MuRF3−/− and sibling wildtype mouse hearts revealed increases in a. PPARα, PPARβ/δ, and PPARγ activity using PPRE-DNA as bait and ELISA
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To further characterize the cardiac hypertrophy in the
MuRF3−/− hearts after 26 weeks high fat diet, we next
did an analysis of cardiomyocyte cross-sectional areas in
perfused fixed histological sections. No differences were
identified when measurements were taken from multiple
animals across multiple levels (Fig. 3a). The hypergly-
cemia of diabetes can contribute to cardiac injury by
multiple mechanisms, including direct and indirect ef-
fects on cardiomyocytes and cardiac fibroblasts. One
hallmark of human diabetic cardiomyopathy is fibrosis
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Fig. 2 MuRF3−/− experience significant deficits in cardiac function after challenge with high fat diet. a qPCR analysis of heart failure associated
fetal gene expression in MuRF3−/− mice at baseline and after 26 weeks high fat diet challenge. b Fasting blood glucose and fasting serum
insulin levels. c Histological analysis of MuRF3−/− and wildtype hearts post-high fat diet challenge. d/e MuRF3−/− mice exhibit an accelerated
heart failure by 6 weeks after the initiation of the high fat diet. Values expressed as Mean ± SE. N indicated in bars (a & b) or below graph (e).
The significance of observed differences in grouped mean values was determined using a One Way ANOVA followed by Holm-Sidak pairwise
post hoc analysis. *p < 0.001, #p < 0.05
Quintana et al. BMC Endocrine Disorders  (2015) 15:36 Page 7 of 18
Table 1 High-resolution transthoracic echocardiography performed on conscious MuRF3−/− and age-matched wild type mice at baseline, 6 weeks, 12 weeks, 15 weeks, 22 weeks,
and 26 weeks high fat diet. Data represent means ± SEM. A One Way ANOVA was performed (¶p < 0.05), followed by Holm-Sidak Multiple Comparison vs. Control Group (MuRF3+/+
26 Weeks High Fat Diet)
MuRF3 MuRF3 MuRF3 MuRF3 MuRF3 MuRF3 MuRF3 MuRF3 MuRF3 MuRF3 MuRF3 MuRF3
+/+ -/- +/+ -/- +/+ -/- +/+ -/- +/+ -/- +/+ -/-
Baseline Baseline 6 Wks
High Fat
Diet
6 Wks
High Fat
Diet
12 Wks
High Fat
Diet
12 Wks
High Fat
Diet
15 Weeks
High Fat
Diet
15 Weeks
High Fat
Diet
22 Wks
High Fat
Diet
22 Wks
High Fat
Diet
26 Weeks
High Fat
Diet
26 Weeks
High Fat
Diet
N=11 N=7 N=9 N=10 N=9 N=10 N=9 N=10 N=9 N=10 N=9 N=10
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12)
AWTD (mm) 1.03±0.02 1.07±0.03 1.14±0.04 0.98±0.04 1.03±0.04 1.01±0.03 1.04±0.04 1.02±0.04 1.09±0.04 1.09±0.02 1.08±0.03 1.06±0.04
AWTS (mm) 1.65±0.04 1.68±0.05 1.78±0.05 1.59±0.03 1.62±0.09 1.60±0.05 1.71±0.06 1.54±0.07 1.66±0.04 1.68±0.04 1.71±0.04 1.60±0.05
LVEDS (mm)¶ 1.25±0.08* 1.33±0.03* 1.45±0.07* 1.70±0.12 1.70±0.12 1.73±0.12 1.75±0.12 2.05±0.12 1.86±0.10 1.85±0.13 1.95±0.06 2.08±0.14
PWTD (mm) 0.99±0.03 1.01±0.06 1.05±0.04 1.00±0.03 0.99±0.04 0.94±0.03 1.00±0.03 0.93±0.04 1.06±0.03 1.03±0.05 1.01±0.04 1.01±0.04
PWTS (mm)¶ 1.65±0.07 1.64±0.06 1.63±0.05 1.43±0.07 1.52±0.09 1.37±0.07 1.51±0.09 1.31±0.04* 1.49±0.07 1.46±0.08 1.50±0.05 1.37±0.07
LV Vol;d (μl) 31.3±3.9 33.8±1.7 37.0±2.7 34.8±3.5 38.0±2.4 31.1±4.0 38.6±3.8 40.5±4.3 42.2±2.9 38.6±4.8 49.0±4.1 45.1±6.1
LV Vol;s (μl)¶ 4.1±0.7* 4.5±0.3* 5.8±0.7* 8.8±1.3 9.0±1.5 9.5±1.8 9.8±1.7 14.2±2.0 11.0±1.4 11.3±2.2 12.0±0.9 15.1±2.6
LV Mass/BW (mg/g) 4.33±0.21* 5.42±0.29* 4.11±0.21* 3.89±0.11* 3.16±0.15 3.16±0.25 3.04±0.16 3.40±0.10 3.18±0.10 3.65±0.16 3.35±0.21 3.78±0.17
HR (bpm) 629±15 619±23 676±6 664±13 681±8 674±9 694±8 697±13 656±19 665±7 662±15 659±9
HR, heart rate; ExLVD, external left ventricular diameter; bpm, heart beats per minute; AWTD, anterior wall thickness in cxxdiastole; AWTS, anterior wall thickness in systole; PWTD, posterior wall thickness in diastole;
PWTS, posterior wall thickness in systole; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening, calculated as (LVEDD-LVESD)/LVEDD x 100; EF%, ejec-
tion fraction calculated as (end Simpson’s diastolic volume – end Simpson’s systolic volume)/end Simpson’s diastolic volume * 100
*p < 0.05 vs. MuRF3+/+ 26 Wks High Fat Diet ( )
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[36, 37], so we next investigated fibrosis by analyzing
Masson’s Trichrome stained cross-section using an object-
ive logarithm to analyze blue collagen content (Fig. 3b).
Only minimal amount of fibrosis was detected, with no
differences between MuRF3−/− and wildtype controls
identified. Analysis of cardiac fibroblast numbers by im-
munofluorescent staining of vimentin positive cells simi-
larly found no differences in the number of fibroblasts
present in MuRF3−/− and wildtype controls (Fig. 3c). In a
broader context, these findings illustrate that increased
susceptibility of MuRF3−/− hearts to cardiac hyper-
trophy seen after 26 weeks high fat diet is not due to
changes in fibrosis or underlying differences in cardiac
fibroblast numbers.
PPAR isoform-specific gene expression has been de-
scribed in PPARα, PPARβ, and PPARγ1-specific trans-
genic mouse models [38–40]. While gene overlap exists,
multiple genes are reported to be increased in PPARα,
but not PPARβ (Fig. 4a). Similarly, multiple genes have
been reported increased in PPARβ but not PPARα
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Fig. 3 Histological analysis of cardiac fibrosis. a Cross-sectional analysis of myocytes reveal no differences between MuRF3−/− and wildtype hearts
(Masson’s Trichrome). b Objective blinded computer analysis of fibrosis of MuRF3−/− and wildtype hearts after 26 weeks high fat diet reveals no
significant differences. c Confocal immunofluorescence analysis of vimentin (fibroblasts) in cardiac cross-sections from MuRF3−/− mice after
26 weeks HFD. Values expressed as Mean ± SE. N = 3 WT and N = 3 MuRF3−/−. A Student’s t-test was performed comparing MuRF3−/− vs. MuRF3+/+
groups. #p < 0.05
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transgenic hearts (Fig. 4b) [38–40]. PPARβ and PPARγ1
genes similarly have been described (Fig. 4c, d, respectively
[38–40]). In response to high fat diet, both MuRF3−/− and
wildtype control hearts had increased expression of the
PPARα target genes glut1 and cd36 mRNA by RT-qPCR
analysis (Fig. 4a). Increases in PPARβ fatty acid metab-
olism genes (Fig. 4c), but not PPARβ glucose metabolic
genes (Fig. 4b) were identified. Both MuRF3−/− and
wildtype hearts showed increases in PPARγ1 target
genes 26 weeks after high fat diet challenge (Fig. 4d).
Notably, MuRF3−/− expression levels did not signifi-
cantly differ from sibling wildtype control hearts in any of
the genes investigated (Fig. 4). Together, these studies il-
lustrate that the increases in cardiac mass present in the
MuRF3−/− mice after 26 weeks high fat diet were not due
to differences in PPAR-driven gene expression between
the two groups.
The toxicity of diabetes to the heart has been attrib-
uted to increases in cardiac triglyceride content and the
mishandling of cardiac glycogen [41–45]. Since MuRF3
has been reported in skeletal muscle as well as cardio-
myocytes [10], we next did an analysis of cardiac trigly-
ceride and gastrocnemius muscle as well as liver as a
control. Consistent with the free fatty acid upregulation
of PPAR-regulated fatty acid oxidation and storage seen
in our initial experiments, significant increases in cardiac
triglyceride were identified 26 weeks after high fat diet
challenge (Fig. 5a). With comparable significant increases
in serum cholesterol and triglycerides (Additional file 1:
Figure S1B) both MuRF3−/− and wildtype hearts exhibited
increased accumulation of cardiac triglyceride to the same
extent (Fig. 5a, left panel). Differences in liver and skeletal
muscle triglyceride were not identified (Fig. 5a). No in-
creases in glycogen stores were seen after high fat diet in
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Fig. 4 High fat diet-induced increases in PPAR-regulated gene (mRNA) levels in MuRF3−/− hearts. RT-qPCR analysis of cardiac a. Cardiac PPARα
target gene expression, b. PPARβ-regulated mRNA target genes involved in glucose metabolism, c. PPARβ-regulated mRNA target genes involved
in fatty acid metabolism. d PPARγ1-regulated mRNA target genes. Values expressed as Mean ± SE. The significance of observed differences in
grouped mean values was determined using a One Way ANOVA followed by Holm-Sidak pairwise post hoc analysis. N per group indicated above
graph. *p≤ 0.001, **p < 0.01, #p < 0.05
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the heart, liver, or representative skeletal muscle (Fig. 5b).
MRI analysis of fat mass, lean body mass, and total water
of MuRF3−/− and wildtype mice were performed at base-
line and after 6, 12, and 22 weeks of high fat diet (Fig. 5c).
Consistent with these findings, gastrocnemius, soleus, and
tibialis anterior weights did not differ (Additional file 1:
Figure S1C). Interestingly, MuRF3−/− mice were resistant
to increases in fat mass resulting from the high fat diet in-
take at 6 and 12 weeks, despite recovering these differ-
ences by 22 weeks (Fig. 5c). These studies illustrate that
the MuRF3−/− cardiac hypertrophy and heart failure in
diabetic cardiomyopathy cannot be explained by differen-
tial storage of cardiac triglyceride or glycogen and that dif-
ferences in fat mass were relatively transient.
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Recent studies have implicated the generation of ROS
and activation of NF-κB signaling in the pathogenesis of
diabetic cardiomyopathy [34, 46, 47]. To determine if in-
flammatory signaling or differences in insulin resistance
were present to a different degree in MuRF3−/− hearts,
we quantified cardiac phospho-p65 indicative of acti-
vated NF-κB, pIRS-1, indicative of insulin signaling, and
phospho-cJun as a measure of downstream JNK signal-
ing resulting from oxidative stress [48]. While high fat
diet clearly increased NF-κB activation (phospho-p65/
total p65 protein levels) in both MuRF3+/+ and MuRF3−/−
mice compared to chow diet (Fig. 6a, right two groups
(chow) increased vs. left two groups (HFD challenged),
MuRF3−/− cardiac phospho-p65 levels increased to the
same level as wildtype hearts (Fig. 6a, far right group vs.
MuRF3 +/+ high fat diet). No differences in phospho-IRS-1
or p-cJun were identified after 26 weeks high fat diet chal-
lenge in the present study (Fig. 6b, c, respectively).
Post-translational modification of intracellular proteins
by O-linked N-acetylglucosamine (O-GlcNAc) in diabetes
is a result of the excess glucose that drives the reaction. O-
GlcNAc, in concert with ubiquitin, mediates several aspects
of diabetic cardiomyopathy [49–53]. Therefore, we mea-
sured the amount of O-GlcNAc proteins in MuRF3−/−
hearts, hypothesizing that the loss of MuRF3 cleared fewer
O-GlcNAc-modified proteins to mediate the enhanced car-
diomyopathy seen in vivo. Immunoblot analysis of O-
GlcNAc-modified proteins in MuRF3−/− hearts dem-
onstrated no differences from wildtype hearts when
mice were fed a chow diet or 26 weeks of high fat diet
(Additional file 2: Figure S2). While modest increases
in O-GlcNAc levels were identified after 26 weeks of high
fat diet, as expected with the observed hyperglycemia, dif-
ferences in O-GlcNAc could did not appear to contribute
to exaggerated MuRF3−/− cardiac dysfunction.
As a ubiquitin ligase, MuRF3 has been shown to ubi-
quitinate and degrade specific substrates in vivo and in
vitro [10]. In mice with both MuRF1 and MuRF3
knocked out, accumulation of protein was identified his-
tologically, later identified by mass spectrometry as beta/
slow myosin [10]. Both MuRF1 and MuRF3 were then
found to poly-ubiquitinate beta/slow myosin targeting it
for degradation by the proteasome. One hypothesis we
had in our current model of diabetic cardiomyopathy
was that MuRF3 regulated cardiac PPAR activity by
post-translationally modifying PPAR isoforms. To inves-
tigate this, we first determined the steady state levels of
PPARα, PPARβ, and PPARγ1 in MuRF3−/− hearts by
western blot analysis. Control MuRF3−/− hearts from
mice on a chow diet did not have significantly different
steady state protein levels of PPARα or PPARγ1 (Fig. 7a).
Unexpectedly, PPARβ protein was significantly decreased
in MuRF3−/− hearts. RT-qPCR analysis of PPARα, PPARβ,
and PPARγ1 mRNA in MuRF3−/− hearts revealed that
this baseline decrease in PPARβ could be explained by de-
creased PPARβ mRNA, suggesting that MuRF3 supported
PPARβ through transcriptional regulation (Additional
file 3: Figure S3A). After 26 weeks of high fat diet,
MuRF3−/− hearts showed significantly decreased PPARα
protein (Fig. 7a, left panel). However, no differences in
PPARα mRNA were found (Additional file 3: Figure S3A).
An alternative possibility is that compensatory expression
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of MuRF1 or MuRF2 may be occurring in the MuRF3−/−
hearts, given their overlapping substrate specificities.
However, hearts from control and 26 weeks high fat diet
challenge do not have increased levels of MuRF1 or
MuRF2 suggesting compensatory mechanisms (Additional
file 3: Figure S3B). Contrary to our hypothesis that MuRF3
regulated PPAR activity through post-translational degrad-
ation, the expected accumulation of PPAR isoform(s) were
not identified in MuRF3−/− hearts. Unexpectedly, in fact,
decreases in PPARα and PPARβ were identified after high
fat diet and at baseline, respectively (Fig. 7a).
We next investigated if MuRF3 may be regulating
PPARα, PPARβ, and PPARγ1 through a non-degradatory
mechanism through non-canonical (poly) ubiquitination
mechanisms. To test MuRF3’s ability to ubiquitinate
PPARs, recombinant ubiquitin, E1, E2 (UbcH5c), MuRF3
(E3), and PPARα were incubated and analyzed by western
blot (Fig. 7b). Interestingly, a di-mono-ubiquitination was
identified, with MuRF3’s autoubiquitination demonstrat-
ing the expected canonical poly-ubiquitination that
leads to degradation in vivo. Similarly, MuRF3 di-mono-
ubiquitinated PPARγ1 (Fig. 7d) but did not ubiquitinate
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PPARβ to any extent (Fig. 7c) with robust positive controls
(MuRF3 autoubiquitination). Together, these studies sug-
gest that MuRF3 has the ability to add two single ubiquitin
moieties to PPARα and PPARγ1, but not PPARβ, which
may regulate PPAR activity in vivo.
By non-targeted metabolomics analysis, MuRF3−/− hearts
after 26 weeks high fat diet clearly separated using Princi-
pal Components analysis (PCA) (Fig. 8a). Analysis of in-
dividual components (Fig. 8b) by T-test and Variable
Interdependent Parameters (VIP) analysis identified spe-
cific metabolites that statistically were different from sib-
ling wildtype control hearts (Fig. 8a, lower two panels).
Further analysis of the T-test and VIP significant
metabolites demonstrated enrichment for the peroxisome
and mitochondria (Additional File 4: Figure 4Sa.), involving
glutathione metabolism, taurine and hypotaurine metabol-
ism, and the synthesis and degradation of ketone bodies
(Additional File 4: Figure 4Sb.). The significant metabolites
were enriched for pyruvate carboxylase deficiency, cardio-
genic shock, non-insulin-dependent diabetes mellitus, and
heart failure (Additional File 4: Figure 4Sc.).
Discussion
We determined a role for MuRF3 in the development of
diabetic cardiomyopathy characterized by the early develop-
ment of heart failure and cardiac hypertrophy. Correlating
Fig. 8 Non-targeted cardiac metabolomics of MuRF3−/− mice after 26 Weeks challenge with high fat diet. a Principal components analysis, t-test,
and Variable Importance in the Projection Analysis/Partial Least Squares-Discriminant Analysis (PLS-DA), b Heat map of metabolites identified by
non-targeted GC/MS analysis of cardiac tissue. N = 3/group. Significance determined as p < 0.05
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with MuRF3−/− enhanced PPARα and PPARγ1 activities,
MuRF3 ubiquitinated PPARα and PPARγ with di-mono-
ubiquitin moieties. These non-canonical post-translational
modifications do not result in substrate degradation, con-
sistent with unaltered levels in the MuRF3−/− mice.
Non-targeted metabolomics analysis further identified
defects in MuRF3−/− hearts where altered metabolites
were enriched similarly to those found in pyruvate
decarboxylase deficiency, an enzyme with a PPAR-
response controlling element [54].
The role of MuRF3 to date has focused on its struc-
tural role supporting the microtubule network [1], sec-
ondarily affecting its maintenance of sarcomeric Z and
M-band formation due to these effects on tubulin dy-
namics [7]. MuRF3−/− mice challenged with myocardial
infarction have shown a predisposition to cardiac rup-
ture after MI [9]. Since microtubule stability is reported
to contribute directly to the cardiac dysfunction ob-
served in diabetic cardiomyopathy, loss of MuRF3 may
contribute to the observed cardiac dysfunction in the
current model [55–57]. Recent studies have implicated
the activation of SRF in regulating growth during dia-
betic cardiomyopathy [58, 59]. Since MuRF3 interacts
with SRF to inhibit its activity much in the same way its
highly homologous MuRF1 and MuRF2 family members
do [3, 5], we anticipated MuRF3−/− hearts would exhibit
an exaggerated hypertrophy (HW/BW, LV Mass, etc.).
To our surprise, MuRF3−/− hearts hypertrophied to the
same degree as wildtype controls over time (Fig. 1d,
Fig. 2e, Table 1), illustrating either MuRF3 minimal con-
tribution to regulating SRF during the development of
diabetic cardiomyopathy or potentially its redundant
regulation of SRF with other MuRF family members.
This is the first published report of MuRF3’s upregula-
tion during diabetic cardiomyopathy (Fig. 1c). Analysis of
MuRF3’s promoter regulatory elements 10–20 kb up-
stream and 10 kb downstream have revealed multiple re-
gions for the glucocorticoid receptor (GR), AML1, Lmo2,
POU3F2, CREB, E2F, and E2F-1 (SAB Biosciences, http://
www.genecards.org/cgi-bin/carddisp.pl?gene=TRIM54).
Disease modeling and phenotypic drug screening for dia-
betic cardiomyopathy has revealed the potential for
glucocorticoid receptor involvement [60], diabetic car-
diomyopathy upregulation of CREB [61], and the E2F
family transcription factors, including E2F1 [62]. Given
the detrimental effects of inadequate MuRF3 during the
development of type 2 diabetes seen in the MuRF3−/−
mice, the upregulation of MuRF3 may be investigated
further for its therapeutic potential suggested in the
current studies.
The non-canonical ubiquitination with mono-ubiquitin
moieties in the current study is distinctly different than
previously reported canonical ubiquitination of PPARs in
cancer cells (recently reviewed [63]). The canonical
ubiquitination (non-Lys63 linked poly-ubiquitin chains)
associated with mediating proteasome dependent degrad-
ation was not found in the present study. This non-
degradatory ubiquitin mediated regulation of PPARs has
not been reported in any system previously, including the
heart. Similarly, specific ubiquitin ligases have not been
identified in these processes prior to this identification of
MuRF3. Contrasting to the current literature in cancer
cells whereby poly-ubiquitination and/or degradation of
substrate has been reported, the lack of degradation of
PPARα and PPARγ1 despite mono-di-ubiquitination
(Fig. 7b, 7D) differs significantly. The ubiquitin ligase
14ARF has been reported to di-ubiquitinate p53 in cancer
cells in a manner which inhibits MDM2, another 14ARF
substrate [64]. Like previous reports of multi-ubiquitinated
(e.g., mono- and di-ubiquitination) substrates [65–67],
MuRF3 does not lead to PPAR degradation in the physio-
logical conditions. MuRF3’s multi-ubiquitination may offer
additional clues into the complex regulation of cardiac
PPAR isoforms previously unknown. Another novel finding
in the present study is that cardiac MuRF3 supports the
expression of PPARβ protein (Fig. 7a) at baseline through
supporting its transcription (PPARβ mRNA, Additional
file 3: Figure S3).
In our initial studies, we identified that nuclear PPARβ
activity was increased 3 fold in MuRF3−/− hearts (Fig. 1a),
but steady state protein levels were decreased (Fig. 7a)
along with decreased PPARβ mRNA. Curiously, MuRF3
did not ubiquitinate PPARβ in vitro (Fig. 7c). Since the
PPAR transcription factor involves a number of additional
proteins, including RXRα and co-activators such as PGC-
1, in addition to inhibitors, such as NCoR and SMRT, all
of which can be SUMOylated and/or ubiquitinated [68],
the answer may lie in the complexity and interactivity of
the system. MuRF3−/− hearts may not be degrading a
PPARβ enhancing co-factor, for example, to result in the
enhanced PPARβ binding activity assayed in these studies.
In this case, even the small decrease in PPARβ may not be
enough to counteract the large increases in PPRE affinity
this unknown factor may afford, giving us the results in
the present study. Further molecular characterization of
the PPARβ complex is warranted, given MuRF3’s interest-
ing regulation of it both transcriptionally and through cur-
rently unknown activating factor(s).
Non-targeted metabolomics analysis of baseline MuRF3−/−
hearts recently identified differences [14]. While few dif-
ferences were seen in MuRF3−/− hearts compared to sib-
ling wildtype controls, with significant overlap in PCA
analysis, VIP significance identified taurine, α-monostearin,
aldohexose1, and glutamic acid [14]. In contrast, we identi-
fied clear differences in the MuRF3−/− cardiac metabolo-
mics signature compared to wildtype mice (Fig. 8a). While
the taurine signature was again identified after high fat diet
as it was on a chow diet, a broader array of metabolites
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were identified differentially in MuRF3−/− hearts (see VIP
analysis metabolites and T-test summary, Fig. 8a).
In the diabetic heart, impaired glycolysis and facilita-
tion of the pentose phosphate pathway has recently been
described [69]. In a type 2 diabetes mellitus model
(OLETF), pressure overloading has identified acute
changes in inosine 5-monophosphate and adenosine,
consistent with higher cardiac AMP deaminase activity
and ATP depletion [69]. While such distinctive conclu-
sions cannot be made based solely on the metabolomics
findings, the altered inosine and adenosine has been
identified in critically ICU patients [70] and may indicate
underlying processes leading to the MuRF3−/− cardiac
phenotype in the present study. Alternations in acetoa-
cetate have been described in the heart, which has sig-
nificance given the hearts ability to utilize acetoacetate
by anaplerosis. The substitution of acetoacetate for glu-
cose by anaplerosis, whereby TCA intermediates fill in,
has been tested as an alternate pathway to form 2-
oxoglutarate ex vivo [71]. This may be relevant to the
MuRF3−/− phenotype, if applicable, as heart oxidizing
acetoacetate resulted in decreased flux through 2-
oxoglutarate dehydrogenase prior to contractile failure,
therefore thought to be directly contributing to the
changes in cardiac work [71].
Conclusions
The present study suggests a protective role for MuRF3
in diabetic cardiomyopathy and an unexpected role in
regulating fat storage despite being found only in stri-
ated muscle. MuRF3 is identified as an ubiquitin ligase
that mono-ubiquitinates cardiac PPARα and PPARγ1 ac-
tivities in vivo via post-translational modification, which
appears to support PPAR stability in the context of dia-
betic cardiomyopathy.
Additional files
Additional file 1: Figure S1. Analysis of circulating total cholesterol
and triglyceride and histology in MuRF3−/− mice after high fat diet.
A. Representative H&E analysis of MuRF2−/− and MuRF2+/+ tissue.
B. Fasting total cholesterol and fasting serum triglyceride levels.
C. Organ weights at 26 weeks high fat diet of gastrocnemius, soleus,
and tibialis anterior. Values represent the mean ± SE (N indicated in bars).
Values expressed as Mean ± SE. A one-way ANOVA was performed to
determine significance followed by an all pairwise multiple comparison
procedure (Holm-Sidak method). #p < 0.05.
Additional file 2: Figure S2. Detection of cardiac O-GlcNac Protein
modifications in MuRF3−/− mice after 26 weeks HFD challenge.
A. Densitometric analysis of O-GlcNac/βactin immunoblot (B).
N = 3/group. Values expressed as Mean ± SE. A one-way ANOVA was
performed to determine significance followed by an All Pairwise Multiple
Comparison Procedure (Holm-Sidak method). #p < 0.05.
Additional file 3: Figure S3. mRNA analysis of cardiac PPAR isoform
expression in MuRF3 −/− mice. Quantitative RT qPCR analysis of cardiac
A. PPARα mRNA, PPARβ mRNA, and PPARγ1 mRNA and B. MuRF1 mRNA
and MuRF2 mRNA at baseline and 26 weeks after high fat diet compared to
sibling-matched wildtype hearts. N indicated in bars. A one-way ANOVA was
performed to determine significance followed by an All Pairwise Multiple
Comparison Procedure (Holm-Sidak method). #p < 0.05.
Additional file 4: Figure S4. Enrichment Analysis of Significantly
different Metabolits Sets. A. Enrichment by Location-Associated Metabol-
ite Sets B. Pathway Analysis of Metabolite Sets, and C. Disease-Associated
Metabolite sets determined from VIP significant and t-test significant
metabolites identified. N = 3/group.
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